Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XY03-EA tablets for acute ischemic stroke (phase IIb/III)
CTR20244086Phase 2Active
- Sponsor
- Yiling Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XY03-EA in ischemic stroke, sponsored by Yiling Pharmaceutical. Started Dec 2024; status: active.
02
Drugs
XY03-EA
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20244086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244086.